2-bromo-1-(isopropylsulfonyl)-4-nitrobenzene | 900174-33-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-1-(isopropylsulfonyl)-4-nitrobenzene
• 英文别名: Benzene, 2-bromo-1-[(1-methylethyl)sulfonyl]-4-nitro-；2-bromo-4-nitro-1-propan-2-ylsulfonylbenzene
• CAS: 900174-33-6
• 化学式: C₉H₁₀BrNO₄S
• 分子量: 308.153
• InChiKey: ZBOKJWIBASBIED-UHFFFAOYSA-N

物化性质

• 沸点：
  442.4±45.0 °C(Predicted)
• 密度：
  1.599±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  88.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-bromo-1-(isopropylsulfonyl)-4-nitrobenzene 在 吡啶 、 盐酸 、 platinum(IV) oxide 、 四(三苯基膦)钯 、 氢气 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 正庚烷 、 水 、 二乙胺 、 异丙醇 为溶剂， 95.0 ℃ 、275.8 kPa 条件下， 反应 11.5h， 生成 (R)-methyl (4-(isopropylsulfonyl)-3-(pyrrolidin-2-yl)phenyl)carbamate hydrochloride
  参考文献：
  名称：

  Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors

  摘要：

  Inhibitors of the Tissue Factor/Factor VIIa (TF-FVIIa) complex are promising novel anticoagulants that show excellent efficacy and minimal bleeding in preclinical models. On the basis of a zwitterionic phenylglycine acylsulfonamide 1, a phenylglycine benzylamide 2 was shown to possess improved permeability and oral bioavailability. Optimization of the benzylamide, guided by X-ray crystallography, led to a potent TF-FVIIa inhibitor 18i with promising oral bioavailability, but promiscuous activity in an in vitro safety panel of receptors and enzymes. Introducing an acid on the pyrrolidine ring, guided by molecular modeling, resulted in highly potent, selective, and efficacious TF-FVIIa inhibitors with clean in vitro safety profile. The pyrrolidine acid 20 showed a moderate clearance, low volume of distribution, and a short t(1/2) in dog PK studies.

  DOI：

  10.1021/ml400453z
• 作为产物：
  描述：

  (2-bromo-4-nitrophenyl)(isopropyl)sulfane 在 Oxone 作用下， 以 甲醇 、 水 为溶剂， 以76%的产率得到2-bromo-1-(isopropylsulfonyl)-4-nitrobenzene
  参考文献：
  名称：

  BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

  摘要：

  本发明提供了式(I)的新型苯甲酰胺衍生物：或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药，其中变量A、W、Y、Z、R8和R9如本文所定义。这些化合物是选择性因子VIIa的抑制剂，可用作药物。

  公开号：

  US20100227894A1

文献信息

• BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS
  申请人：Priestley Eldon Scott

  公开号：US20100227894A1

  公开（公告）日：2010-09-09

  The present invention provides novel benzamide derivatives of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, W, Y, Z, R 8 , and R 9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

  本发明提供了式(I)的新型苯甲酰胺衍生物：或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药，其中变量A、W、Y、Z、R8和R9如本文所定义。这些化合物是选择性因子VIIa的抑制剂，可用作药物。
• Synthesis and anticancer activity evaluation of novel azacalix[2]arene[2]pyrimidines
  作者：Yesu Addepalli、Xiaohong Yang、Minghui Zhou、D. Prabhakar Reddy、Shao-Lin Zhang、Zhen Wang、Yun He

  DOI：10.1016/j.ejmech.2018.02.079

  日期：2018.5

  A series of novel azacalix[2]arene[2]pyrimidines were synthesized, and evaluated for their antiproliferative activities against A549, MCF7, SH-SY5Y and CNE human cancer cell lines in vitro by using the CCK-8 assay. A number of compounds showed low micromolar antiproliferative activities against MCF7 cell line. Compound 4j, containing a pyrrolidine moiety, exhibited the strongest inhibitory activity

  合成了一系列新颖的氮杂杯[2]芳烃[2]嘧啶，并通过CCK-8测定了其体外对A549，MCF7，SH-SY5Y和CNE人癌细胞系的抗增殖活性。许多化合物对MCF7细胞系表现出低的微摩尔抗增殖活性。含有吡咯烷部分的化合物4j表现出最强的抑制活性，IC 50值为0.58μM。此外，乳腺癌细胞被用来探索这些azacalix [2] arene [2] pyrimidines的抑制机制。结果表明这些化合物参与通过以下途径诱导细胞凋亡caspase-3和caspase-9蛋白表达上调，细胞周期停在S期。我们的报告在这里代表了对azacalix [2] arene [2] pyrimidines的生物学活性的首次研究。
• Phenylglycinamide derivatives useful as anticoagulants
  申请人：Zhang Xiaojun

  公开号：US20060166997A1

  公开（公告）日：2006-07-27

  The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

  本发明一般涉及抑制丝氨酸蛋白酶的苯基甘氨酰衍生物。具体而言，本发明涉及新型苯基甘氨酰衍生物及其类似物，其可用作凝血级联反应的丝氨酸蛋白酶酶的选择性抑制剂；例如凝血酶、第VIIa因子、第Xa因子、第XIa因子、第IXa因子和/或血浆激肽。特别是，它涉及到的化合物是第VIIa因子的抑制剂。本发明还涉及包含这些化合物的制药组合物及其使用方法。
• BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS
  申请人：Wurtz Nicholas Ronald

  公开号：US20100041664A1

  公开（公告）日：2010-02-18

  The present invention provides novel bicyclic lactams derivatives, and analogues thereof, of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, B, C, W, Y, Z 1 , Z 2 , Z 3 , Z 4 , R 8 , and R 9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

  本发明提供了新型双环内酰胺衍生物及其类似物，其化学式为(I)：或其立体异构体、互变异构体、药学上可接受的盐、溶剂化物或前药。其中，变量A、B、C、W、Y、Z1、Z2、Z3、Z4、R8和R9的定义如本文所述。这些化合物是选择性因子VIIa抑制剂，可用作药物。
• Benzamide factor VIIa inhibitors useful as anticoagulants
  申请人：Bristol-Myers Squibb Company

  公开号：US08222453B2

  公开（公告）日：2012-07-17

  The present invention provides novel benzamide derivatives of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, W, Y, Z, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

  本发明提供一种新的苯甲酰胺衍生物，其化学式为(I)：或其立体异构体、互变异构体、药学上可接受的盐、溶剂化合物或前药，其中变量A、W、Y、Z、R8和R9如本文所定义。这些化合物是选择性因子VIIa抑制剂，可用作药物。